A5091532757- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- HER2/EGFR in Cancer Research
- Medical Imaging and Pathology Studies
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Ovarian cancer diagnosis and treatment
- Occupational and environmental lung diseases
- Pleural and Pulmonary Diseases
- Brain Metastases and Treatment
- Functional Brain Connectivity Studies
- Renal Diseases and Glomerulopathies
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Mechanisms and Therapy
- Neuroblastoma Research and Treatments
- Mental Health Research Topics
- Cancer Immunotherapy and Biomarkers
Foro Italico University of Rome
2023-2025
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2014-2025
Federico II University Hospital
2005-2024
University of Naples Federico II
1979-2024
Institute of Cognitive Sciences and Technologies
2023
National Research Council
2023
Sapienza University of Rome
2023
Swinburne University of Technology
2023
University of Campania "Luigi Vanvitelli"
2020
Istituti di Ricovero e Cura a Carattere Scientifico
2018
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were available non-Asian patients. BEVERLY is an Italian, multicenter, randomized, phase 3 investigating addition as first-line treatment NSCLC.Eligible randomized 1:1 plus or alone. Investigator-assessed PFS and blinded independent centrally reviewed coprimary end points. With 80% power detecting a 0.60 hazard ratio two-sided...
Purpose To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) within a combined analysis two parallel phase III trials, MILES-3 and MILES-4. Patients Methods NSCLC who were older than age 70 years Eastern Cooperative Oncology Group performance status 0 1 randomly assigned gemcitabine or pemetrexed, without cisplatin. In each trial, 382 events required detect hazard ratio (HR) death 0.75, 80% power two-tailed α...
Flexible goal-directed human cognition is supported by many forms of self-directed manipulation representations. Among them, Inner-Speech (IS; covert speech) acts on second-order representations (e.g., goals/sub-goals), empowering attention and feedback processing. Interestingly, patients with Schizophrenia Spectrum Disorders (SSD) show impaired Executive Functions (EF; e.g., cognitive flexibility) and, probably, a related IS alteration. However, fragmentary evidence no computational...
// Gennaro Chiappetta 1,* , Anna Basile 2,3,* Antonio Barbieri 4 Antonia Falco 2,3 Alessandra Rosati Michelina Festa Rosa Pasquinelli 1 Daniela Califano Giuseppe Palma Raffaele Costanzo 5 Barcaroli 6 Mario Capunzo 7 Renato Franco 8 Gaetano Rocco 9 Maria Pascale Caterina Turco 3,7 Vincenzo De Laurenzi 3,6 and Claudio Arra Functional Genomic Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, Italy 2 Department of Pharmacy, University...
The sequential doxorubicin --> CMF (CMF=cyclophosphamide, methotrexate, fluorouracil) regimen has never been compared to in a randomised trial. role of adding goserelin and tamoxifen after chemotherapy is unclear. In all, 466 premenopausal node-positive patients were to: (a) x 6 cycles (CMF); (b) 4 followed by (A CMF); (c) plus 2 years (CMF GT); (d) GT). study used factorial experimental design assess: (1) the effect regimens vs A or arms a+c b+d) (2) GT (arms a+b c+d). At median follow-up...